Swiss firm Telormedix raises CHF21 million
This article was originally published in Scrip
Executive Summary
Telormedix, a new Swiss biotechnology company, has raised CHF21 million ($18 million) in a series A financing, one of the largest rounds in Switzerland for biotech start-ups this year.